Recurrent Pityriasis Versicolor Clinical Trial
Official title:
Detection of IL1-7A and IL-17F Gene Polymorphism in Pityriasis Versicolor and Its Relation to Susceptibility to Infections.
Blood samples will be taken from cases presenting with recurrent tinea versicolor , after confirmation of diagnosis by wood's light and KOH examination, for the detection of gene polymorphism in IL17 A and IL17 F. In addition , serum samples from patients and controls will be tested for 25(OH)2 D3
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | November 1, 2021 |
| Est. primary completion date | June 1, 2021 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years to 60 Years |
| Eligibility | Inclusion Criteria: - - Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it. - Patients of both genders. - Age =18 years old. Exclusion Criteria: - - Patients with other cutaneous diseases. - Patient's having dandruff (scaly scalp) even if not symptomatizing. - Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects. - Patients with autoimmune diseases. - Patients with immunodeficiency diseases. - Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone. |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Kasr Al Ainy Hospital, Cairo university | Cairo | El Manial |
| Lead Sponsor | Collaborator |
|---|---|
| Kasr El Aini Hospital |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | IL 17A gene polymorphism | IL 17A | 6months-1 year | |
| Primary | IL 17 F gene polymorphism | IL 17 F | 6months-1 year | |
| Secondary | Vitamin D | Serum 25(OH)2 D3 | 6months-1 year |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05067699 -
Vitamin D Level in Recurrent PV
|